Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
44 participants
INTERVENTIONAL
2025-12-31
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
NCT06015230
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
NCT07122076
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
NCT06530849
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GR1803 injection dose 1
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
GR1803 injection dose 2
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
GR1803 injection dose 3
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
GR1803 injection dose 4
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SLEDAI-2K≥6分
* written informed consent and ability to comply with protocol requirements
* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Exclusion Criteria
* active infection
* history of malignant tumor within 5 years
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Professor Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GR1803-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.